Howard Kaufman, MD
Affiliations: | 1986-2000 | Neurosurgery | West Virginia University, Morgantown, WV, United States |
Google:
"Howard Kaufman"Mean distance: (not calculated yet)
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Silk AW, Kaufman HL, Curti B, et al. (2019) High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma. Frontiers in Oncology. 9: 1483 |
| Fishman M, Dutcher JP, Clark JI, et al. (2019) Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIM registry. Journal For Immunotherapy of Cancer. 7: 84 |
| Middleton MR, Sacco JJ, Merchan JR, et al. (2019) An open label, multicenter, phase I/II study of RP1 as a single agent and in combination with PD1 blockade in patients with solid tumors. Journal of Clinical Oncology. 37 |
| D'Angelo SP, Russell J, Lebbé C, et al. (2018) Efficacy and Safety of First-line Avelumab Treatment in Patients With Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial. Jama Oncology |
| Wagner J, Kline CL, Zhou L, et al. (2018) Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation |
| Kaufman HL, Russell JS, Hamid O, et al. (2018) Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. Journal For Immunotherapy of Cancer. 6: 7 |
| Dorff TB, Wong MKK, Clark J, et al. (2018) High dose interleukin-2 and response in 944 patients with metastatic renal cell cancer (RCC): Data from the PROCLAIM registry. Journal of Clinical Oncology. 36: 624-624 |
| Silk AW, LeBoeuf NR, Rabinowits G, et al. (2018) A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057). Journal of Clinical Oncology. 36: TPS219-TPS219 |
| Fishman MN, Clark JI, Alva AS, et al. (2018) Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM. Journal of Clinical Oncology. 36: 4578-4578 |
| Chesney J, Puzanov I, Collichio F, et al. (2017) Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2017737379 |